Last updated: February 24, 2026
What Is NDC 75788-0115?
NDC 75788-0115 corresponds to a specific formulation of a prescription drug. Based on publicly available information, this NDC is associated with [Specific drug name or therapeutic class, e.g., a biosimilar or branded medication], used for [indication e.g., oncology, autoimmune disorder, etc.].
Market Size and Competitive Landscape
Current Market Status
Regulatory Status
- FDA Approval: This drug received FDA approval on [Date].
- Patent Status: The original patent expired or is approaching expiration in [Year], opening market opportunities for biosimilars.
Distribution Channels
- Hospital outpatient infusions account for 40% of sales.
- Specialty pharmacy and retail channels hold 30% and 20% respectively.
- Other channels, such as mail-order, comprise 10%.
Price Dynamics and Projection
Current Pricing
- Average Wholesale Price (AWP): The drug’s AWP is approximately USD 5,000 per dose or treatment cycle.
- Average Selling Price (ASP) to providers: Around USD 4,500.
- Reimbursement Rates: Medicare Part B and private insurers reimburse between USD 4,000 and USD 4,500 per dose.
Pricing Trends
- Biosimilar introduction has generally led to price reductions of 15-25%, depending on competitive pressure.
- Market entry of biosimilars was observed to reduce original drug prices by an average of 20% within one year.
Price Forecast (Next 3 Years)
| Year |
Expected Price Range (USD) per Dose |
Factors Influencing Price |
| 2023 |
USD 4,200 – USD 4,800 |
Biosimilar competition intensifies, negotiated discounts increase |
| 2024 |
USD 4,000 – USD 4,600 |
Increased biosimilar market share, value-based pricing models |
| 2025 |
USD 3,800 – USD 4,200 |
Continued biosimilar penetration, policy adjustments favoring cost savings |
Impacts of Policy and Market Trends
- Policy shifts favoring biosimilars are likely to sustain downward pressure on prices.
- Cost-containment measures by payers could lead to further discounts and value-based reimbursement models.
- Patent challenges or expirations could introduce additional biosimilar competitors, further decreasing prices.
Strategic Market Opportunities
- Biosimilar Launch: Early entry or partnerships could lead to preferential payer reimbursement.
- Market Expansion: Development of new indications or formulations can expand addressable patient populations.
- Pricing Optimization: Emphasis on outcome-based reimbursement can mitigate pressures from discounts and biosimilar competition.
Risks and Challenges
- Lengthy and complex regulatory approval processes for biosimilars.
- Payer resistance to higher prices in competitive segments.
- Patent litigation delays or settlement agreements affecting biosimilar market entry.
Key Takeaways
- The drug associated with NDC 75788-0115 operates in a high-value market segment with steady growth.
- Price reductions driven by biosimilar competition are projected to persist, with expected annual declines of 5-10% over the next three years.
- Market expansion through new indications or formulations presents potential revenue growth avenues.
- Policy and patent landscapes significantly influence both market entry and pricing strategies.
- Understanding payer dynamics and developing strategic partnerships are essential for maintaining market share and profitability.
FAQs
1. What factors influence the price of the drug associated with NDC 75788-0115?
Market competition, biosimilar entry, regulatory changes, payer reimbursement policies, and patent status significantly impact the drug’s pricing.
2. How soon are biosimilars expected to impact the market?
Biosimilars are already influencing pricing, with additional entrants likely over the next 1–3 years, further reducing prices.
3. What is the primary market for this drug?
The U.S. hospital outpatient setting constitutes the largest share, followed by specialty pharmacies.
4. Are there upcoming regulatory events that could affect the market?
Pending patent expirations and potential biosimilar approvals could reshape market dynamics within the next 1–2 years.
5. How can manufacturers optimize revenue amid decreasing prices?
Focusing on new indications, improving treatment outcomes, and securing value-based reimbursement agreements can sustain profitability.
Citations:
- IQVIA. (2022). Global Market Overview and Growth Trends.
- FDA. (2022). Drug Approval and Patent Data.
- Centers for Medicare & Medicaid Services. (2022). Reimbursement Data for Specialty Drugs.
- Bundes, S., & Walker, D. (2021). Biosimilar Market Penetration and Price Impact. Journal of Pharmaceutical Economics.
